Insights

The ongoing reform of the EU pharmaceutical legislation is entering a crucial phase. After more than 20 years since the last comprehensive revision, the European Commission’s ambitious proposal aims to create a more agile, competitive, and equitable regulatory framework. In this article, we summarize the key recent updates, the next steps in the legislative process, and highlight some of the most debated aspects from the perspective of the pharmaceutical industry and stakeholders.

Brief Recap: How We Got Here

• April 2023: The European Commission published its long-awaited proposal for a new Regulation (replacing Regulation 726/2004) and Directive (replacing Directive 2001/83/EC).
• The reform focuses on improving access to medicines, strengthening EU competitiveness, tackling supply chain shortages, addressing environmental impact, and streamlining regulatory processes.
• April 2024: The European Parliament adopted its position, advocating for longer data protection periods and additional incentives for innovation.

Latest Updates (as of June 2025)

• June 4, 2025: The Council of the European Union (under the Belgian Presidency) adopted its position:
  • Regulatory Data Protection (RDP): Set at 8 years, with Market Protection (MP) reduced from 2 years to 1 year. MP can be extended by up to 1 additional year if certain conditions are met (e.g., unmet medical need, clinical trials conducted in the EU).
  • Obligation to Supply: Introduces binding obligations for companies to ensure product availability across Member States, with the possibility of penalties for non-compliance.
  • Orphan Medicinal Products (OMPs): Retains 10 years of exclusivity, but introduces a “Global Orphan” system to avoid double protection if products are already marketed elsewhere.
  • Transferable Exclusivity Vouchers (TEVs): Introduced to incentivize the development of new antimicrobials.
  • Bolar Exemption: Expanded to facilitate generic entry, including exemptions for tendering and responsible generics development.
• Interinstitutional negotiations (Trilogues): Officially launched on June 17, 2025, marking the start of final political negotiations. A potential agreement expected in late 2025.

Key Points of Controversy

The reform package has triggered significant debate among industry stakeholders, patient organizations, Member States, and academia:

• Reduced IP Incentives: Many pharmaceutical companies and trade associations (including EFPIA) argue that shorter protection periods could make the EU less attractive for investment in R&D, shifting innovation efforts to markets with stronger IP frameworks such as the US or Asia.
• Obligation to Supply: Industry representatives have voiced concerns about the feasibility and legal implications of mandatory supply obligations, especially for products with limited demand or complex manufacturing chains.
• Environmental Requirements: The introduction of a mandatory “quaternary treatment” to address pharmaceutical residues in wastewater has been criticized as placing disproportionate burdens on the industry compared to other sectors.
• Transferable Vouchers: While intended to stimulate antimicrobial innovation, transferable exclusivity vouchers remain controversial, with doubts about their cost-effectiveness and potential unintended consequences for access and affordability.

Main Differences Compared to Current Legislation

What’s Next? Timeline & Expected Entry into Force

• June 17, 2025: Trilogue negotiations officially started.
• Late 2025: Possible political agreement and adoption.
• 2026: Formal publication of the new Regulation and Directive.
• Entry into force:
  • Regulation: 20 days after publication (immediate applicability).
  • Directive: Transposition period of up to 36 months (~2029 full implementation across Member States).

Implications for the Pharmaceutical Industry

This reform will have far-reaching implications for companies active in regulatory affairs, market access, and pharmaceutical development:

• Companies will need to reassess launch strategies, IP management, and market access planning across the EU.
• The balance between encouraging innovation and accelerating access to generics and biosimilars remains at the center of political debates.
• Increased environmental obligations may lead to significant investments in greener production processes and infrastructure.
• Early engagement with regulators, payers, and national authorities will be key to successfully navigating the new framework.

The EU pharma legislation reform is one of the most comprehensive regulatory overhauls in recent years. As the legislative process moves toward finalization, companies should proactively prepare to adapt to the evolving landscape.

Regulatory Pharma Net provides full regulatory assistance during the whole product lifecycle and is ready to support companies on all regulatory needs and to guide them through the future European Pharma landscape.